<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00005074</url>
  </required_header>
  <id_info>
    <org_study_id>I127</org_study_id>
    <secondary_id>CAN-NCIC-IND127</secondary_id>
    <secondary_id>NCI-100</secondary_id>
    <secondary_id>CDR0000067679</secondary_id>
    <nct_id>NCT00005074</nct_id>
  </id_info>
  <brief_title>Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma</brief_title>
  <official_title>A Phase II Study of Flavopiridol (HMR 1275; NSC 649890) in Patients With Untreated or Relapsed Mantle Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Canadian Cancer Trials Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing&#xD;
      so they stop growing or die.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of flavopiridol in treating patients who&#xD;
      have previously untreated or relapsed mantle cell lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Assess the efficacy of flavopiridol in terms of response rate in patients with&#xD;
           previously untreated or relapsed mantle cell lymphoma.&#xD;
&#xD;
        -  Assess the toxicity of this regimen in this patient population.&#xD;
&#xD;
        -  Determine the time to progression and, if responses are observed, response duration in&#xD;
           these patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients receive flavopiridol IV over 1 hour daily for 3 days. Treatment continues every 3&#xD;
      weeks in the absence of unacceptable toxicity or disease progression. Patients with a&#xD;
      complete response (CR) receive 2 additional courses after documented CR. Patients with a&#xD;
      partial response receive 2 additional courses after documented maximal tumor shrinkage.&#xD;
      Patients with stable disease receive a maximum of 4 courses.&#xD;
&#xD;
      Patients are followed at 4 weeks and then every 3 months until relapse or death.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study within 18-24&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2000</start_date>
  <completion_date type="Actual">September 22, 2008</completion_date>
  <primary_completion_date type="Actual">February 20, 2002</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">33</enrollment>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alvocidib</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed mantle cell lymphoma (at initial diagnosis)&#xD;
             nonrefractory to prior therapy or with no prior therapy&#xD;
&#xD;
               -  No documented disease progression while receiving prior chemotherapy&#xD;
&#xD;
          -  CD20 and CD5 positive&#xD;
&#xD;
          -  Presence of clinically and/or radiologically documented disease&#xD;
&#xD;
          -  At least 1 site of disease must be bidimensionally measurable&#xD;
&#xD;
               -  Bone lesions not considered bidimensionally measurable&#xD;
&#xD;
               -  Minimum indicator lesions must be:&#xD;
&#xD;
                    -  Lymph nodes at least 1.5 cm x 1.5 cm by physical exam or spiral CT scan OR&#xD;
&#xD;
                    -  Other nonnodal lesions at least 1 cm x 1 cm by MRI, CT scan, or physical&#xD;
                       exam&#xD;
&#xD;
          -  No known CNS involvement by lymphoma&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Absolute granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 75,000/mm3&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit or normal (ULN)&#xD;
&#xD;
          -  AST no greater than 2.5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No clinically significant cardiac symptomatology&#xD;
&#xD;
          -  If history of cardiac disease, cardiac ejection fraction greater than 50%&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No clinically significant pulmonary symptomatology&#xD;
&#xD;
          -  If history of symptomatic pulmonary disease:&#xD;
&#xD;
               -  FEV1, FVC, and TLC greater than 60% predicted&#xD;
&#xD;
               -  DLCO greater than 50% predicted&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Must be accessible for treatment and follow-up (i.e., no geographical limitations)&#xD;
&#xD;
          -  No uncontrolled bacterial, fungal, or viral infection&#xD;
&#xD;
          -  No other serious concurrent disease&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  No prior radioactive monoclonal antibody therapy&#xD;
&#xD;
          -  Prior rituximab allowed&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens allowed&#xD;
&#xD;
          -  Same chemotherapy combination given for first line and second line therapy considered&#xD;
             2 regimens&#xD;
&#xD;
          -  At least 6 weeks since prior chemotherapy&#xD;
&#xD;
          -  No prior high-dose chemotherapy and stem cell transplantation&#xD;
&#xD;
          -  No other concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  No prior radiotherapy to greater than 25% of functioning bone marrow&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy (except low-dose, non-myelosuppressive&#xD;
             radiotherapy) and recovered&#xD;
&#xD;
          -  No concurrent radiotherapy to sole site of measurable disease&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  At least 2 weeks since prior major surgery&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No other concurrent investigational anticancer agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph M. Connors, MD</last_name>
    <role>Study Chair</role>
    <affiliation>British Columbia Cancer Agency</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nova Scotia Cancer Centre</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 1V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Ontario-Hamilton Regional Cancer Centre</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8V 5C2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Humber River Regional Hospital</name>
      <address>
        <city>Weston</city>
        <state>Ontario</state>
        <zip>M9N 1N8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Kouroukis CT, Belch A, Crump M, Eisenhauer E, Gascoyne RD, Meyer R, Lohmann R, Lopez P, Powers J, Turner R, Connors JM; National Cancer Institute of Canada Clinical Trials Group. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003 May 1;21(9):1740-5. doi: 10.1200/JCO.2003.09.057.</citation>
    <PMID>12735303</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>stage II mantle cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alvocidib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

